Daniela Dimarco, MD

This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.

By itself, the POET trial should not fundamentally change the current approach to infective endocarditis treatment.